Connect with us

Wellness

WHO launches AI tool for reproductive health information

Published

on

The World Health Organization (WHO) has launched an AI tool in beta to help policymakers, experts and healthcare professionals access sexual and reproductive health information faster.

Called ChatHRP, the tool was created by WHO’s Human Reproduction Programme and draws only on verified research and guidance collected by HRP and WHO.

It uses natural language processing and retrieval-augmented generation to produce referenced content and cut the time spent searching through documents across different platforms and databases.

WHO said ChatHRP also has multilingual capabilities and low-bandwidth functionality to support use in a wide range of settings.

The beta-testing phase is aimed at a broad professional audience, including policymakers, healthcare workers, researchers and civil society groups.

WHO said the tool can help users quickly access up-to-date evidence, find sources for academic work and verify information on sexual and reproductive health and rights.

Examples of questions it can answer include the latest violence against women data in Oceania for women aged 15 to 49, recommendations on managing diabetes during pregnancy, and whether PrEP and contraception can be used at the same time. PrEP is medicine used to reduce the risk of getting HIV.

WHO added that the system will be updated regularly as new HRP materials are published and includes a feedback loop so users can flag gaps in the information provided.

The launch comes amid wider concern about misinformation in sexual and reproductive health.

A 2025 scoping review found that misinformation in digital spaces is a systemic issue that can undermine human rights, reinforce discriminatory social norms and exclude marginalised voices.

The review also said misinformation can affect health systems by shaping provider knowledge and practice, disrupting service delivery and creating barriers to equitable care.

WHO said ChatHRP is intended to give users streamlined access to reliable information as a counter to “algorithms, opinions, or misinformation”.

Events

Women’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage

Published

on

Women’s HealthX has announced its lineup of healthcare trailblazers speaking on Chronic Disease Management, alongside other specialisations including Fertility, Sexual Health, Maternity, Menopause and Cognitive Health, taking a holistic approach to women’s health.

It will bring together 750+ leaders across pharma, health systems, and innovation to address one of the most urgent and underexamined challenges in healthcare; the sex difference gap in data and evidence.

Since cardiovascular disease remains the leading cause of death among women globally, and autoimmune and neurological conditions affect women at significantly higher rates, Women’s HealthX will home in on chronic disease management with 17+ sessions spotlighting case studies and lessons learned.

The Chronic Disease Management Stage at Women’s HealthX responds directly to this gap, convening senior decision makers and innovators to explore how sex specific science, digital health, and new care models can reshape outcomes for women.

Attending pharma & healthcare organisations include:

  • Tracy Sims, Executive Director, Cardiometabolic Health, Eli Lilly
  • Adrian Kielhorn, Senior Director, Global Head HEOR Neurology, Alexion Pharmaceuticals
  • Lauren Powell, Head of Health Equity and Clinical Innovation, Biogen
  • Amy Kao, SVP, Head of Neuroscience and Immunology Research, EMD Serono
  • Stella Vnook, Executive Chair and CEO, Kaida Biopharma
  • Amanda Borsky, Director, Clinical Research, Northwell Health
  • Lacey McIntosh, Division Chief, Oncologic and Molecular Imaging, UMass Memorial Medical Center
  • Nicole Turck, Vice President Operations, Women’s Health, Corewell Health
  • Mette Dyhrberg, CEO, Autoimmune Registry
  • Lyn Agostinelli, Principal Consultant, Halloran Consulting Group

Sessions addressing the real gaps in women’s chronic care

The agenda features a series of high impact sessions tackling the structural and scientific gaps in women’s health:

  • Improving outcomes in obesity through evidence based person centered care: Eli Lilly
  • Tackling sex based health inequities by breaking down barriers and bias: Alexion Pharmaceuticals
  • Close the health equity gap in women’s health by improving how autoimmune diseases are diagnosed, treated and managed: Autoimmune Registry
  • How a GYN only care model is driving faster access to gynecological care: Corewell Health
  • Transforming early detection in ovarian cancer: new pathways to accuracy, safety, and better outcomes: UMass Memorial Medical Center

Panel discussions include:

  • Why chronic disease looks different in women and why health systems haven’t adapted: Biogen, Kaida Biopharma, EMD Serono
  • How can we better engage with our customers: Northwell Health, Halloran Consulting Group

Health equity starts here. REGISTER YOUR PLACE

Why This Matters Now

Women’s HealthX positions chronic disease not just as a clinical challenge, but as a critical frontier for innovation, investment, and system redesign.

From AI powered monitoring and digital therapeutics to real world data and integrated care pathways, the stage highlights where meaningful progress is already being made and where the biggest opportunities lie.

For the FemTech ecosystem, this represents a pivotal moment: aligning technology, clinical insight, and commercial strategy to finally close the long standing data and care gaps in women’s health.

About Women’s HealthX

Women’s HealthX is where the transformation of women’s health begins at its true foundation: data, science, and evidence.

It’s the leading event dedicated to closing the sex difference data gap and accelerating breakthroughs through science driven, real world case studies.

Taking place on December 3 to 4, 2026 in Boston, USA, the exhibition will bring together more than 750 healthcare leaders, including clinicians, payers, employers, investors, and policymakers.

Seven different stages with 150+ expert speakers taking an holistic approach to women’s health. From fertility, maternity, sexual health, cognitive health, menopause and chronic disease, we address care at every stage of a woman’s life.

Continue Reading

Wellness

Elimination of cervical cancer in EU an ‘achievable goal’, report finds

Published

on

Cervical cancer elimination in the EU is becoming achievable as HPV vaccination coverage rises, a new report says.

As Europe marks European Immunisation Week 2026, the European Centre for Disease Prevention and Control said progress in human papillomavirus vaccination is continuing across the EU and European Economic Area.

All EU and European Economic Area countries now recommend HPV vaccination for adolescent girls and boys as part of their immunisation programmes, marking a major step forward in Europe’s cancer prevention efforts.

Bruno Ciancio, head of unit, directly transmitted diseases and vaccine preventable diseases at the European Centre for Disease Prevention and Control, said: “The elimination of cervical cancer in the EU/EEA is becoming an achievable goal, thanks to the HPV vaccination programmes.

“The progress we are seeing across Europe demonstrates what can be accomplished when countries invest consistently in effective immunisation strategies.

“We are closely monitoring this progress and actively supporting countries to accelerate uptake and move faster towards cervical cancer elimination.”

According to the report, three EU and European Economic Area countries, Iceland, Portugal and Norway, have reached the 2024 EU Council Recommendation target of 90 per cent HPV vaccination coverage among girls by the age of 15.

Fifteen years after HPV vaccination programmes were introduced in Europe, a growing body of evidence confirms the vaccine is highly effective in preventing cervical cancer.

Large-scale studies from Sweden, the Netherlands and Denmark, as well as other parts of the world, have shown significant reductions in HPV infections and precancerous lesions, which are abnormal cell changes that can develop into cancer if left untreated, alongside falling cervical cancer rates among vaccinated women.

Since 2020, European countries have reported a decreased incidence of cervical cancer among vaccinated women.

Studies from Sweden, Denmark and the UK show that early administration of the vaccine increases its full protective potential.

A Swedish study suggested that vaccinating girls before their 17th birthday reduced the incidence of cervical cancer by 88 per cent.

An additional six-year follow-up found a sustained reduction in cervical cancer risk and a population-level decline in invasive cervical cancer incidence after HPV vaccination.

The report showed that vaccination programmes and health system design are critical factors in reaching high levels of HPV vaccination coverage.

Evidence from across Europe showed that school-based vaccination programmes are particularly effective and tend to reach higher levels of coverage among both girls and boys.

Continue Reading

Wellness

Poor mental health, poverty and pollution significantly raise women’s heart failure risk – study

Published

on

Poor mental health, poverty and pollution can raise women’s heart failure risk, with up to one in four cases potentially preventable, a study has found.

UK Biobank data from more than 230,000 women suggest that depression, socioeconomic hardship and exposure to polluted environments are linked to a significantly higher risk of heart failure in women.

Heart failure happens when the heart becomes too weak or too stiff to pump blood effectively around the body.

High blood pressure, high cholesterol, smoking and diabetes are among the better-known risk factors often targeted in public health campaigns.

Peige Song from China’s Zhejiang University and her team found that living in polluted areas, having poor mental wellbeing, facing socioeconomic deprivation and experiencing chronic inflammatory conditions such as lupus, in which the immune system attacks the body’s own tissues, make women more prone to heart failure.

These risks, however, are often overlooked.

The researchers found that mental wellbeing, environmental exposures, socioeconomic circumstances and reproductive history together contributed almost as much risk for heart failure as all well-known risk factors combined.

The study also found that risk rises with socioeconomic hardship and chronic inflammatory conditions such as lupus or rheumatoid arthritis, approaching the impact of conventional risk factors.

Song said: “[The study] is a call to redefine prevention in women’s cardiovascular health, integrating biological, psychosocial and structural determinants into a unified, equitable approach.

“One in four heart-failure cases in women could be prevented if all under-recognised risk factors were eliminated, assuming causal relationships.”

While completely eliminating all risks is not realistic, Song said “even partial reductions through better mental health services, social equity policies and environmental regulations could yield significant public health benefits”.

Catherine Pirkle, a women’s health specialist at the University of Hawaiʻi at Mānoa in the US, who was not involved in the study, said: “These calculations show convincingly that under-recognised and female-specific risk factors contribute significantly to heart failure in women, independently of the well-established ones.”

Song said: “It’s important to understand that heart health is influenced by more than just blood pressure or cholesterol.

“Factors like mental wellbeing, reproductive milestones and socioeconomic conditions all matter. Awareness and advocacy for comprehensive, gender-sensitive care are key.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.